Zelira Therapeutics (ASX:ZLD) Other Current Receivables: A$0.03 Mil (As of Jun. 2025)


What is Zelira Therapeutics Other Current Receivables?

Zelira Therapeutics ASX:ZLD Other Current Receivables is A$0.03 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Zelira Therapeutics's Other Current Receivables for the quarter that ended in Jun. 2025 was A$0.03 Mil.

Zelira Therapeutics's quarterly Other Current Receivables declined from Jun. 2024 (A$0.19 Mil) to Dec. 2024 (A$0.00 Mil) but then increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.03 Mil).

Zelira Therapeutics's annual Other Current Receivables increased from Jun. 2023 (A$0.01 Mil) to Jun. 2024 (A$0.19 Mil) but then declined from Jun. 2024 (A$0.19 Mil) to Jun. 2025 (A$0.03 Mil).

Zelira Therapeutics Other Current Receivables Related Terms

Zelira Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Other Current Receivables Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.16 0.01 0.19 0.03

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.19 0.00 0.03

Zelira Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of A$0.03 Mil mean?
Zelira Therapeutics (ASX:ZLD) has a Other Current Receivables of A$0.03 Mil as of Jun. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Other Current Receivables too high?
Zelira Therapeutics' current Other Current Receivables is A$0.03 Mil.
How does Zelira Therapeutics' Other Current Receivables compare to MTNB and SXTP?
Zelira Therapeutics' Other Current Receivables of A$0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Other Current Receivables is A$0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Other Current Receivables of A$0.03 Mil. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Other Current Receivables is A$0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Other Current Receivables is A$0.03 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.